Congenital heart disease is a common problem in children with Down syndrome (DS). Echocardiography plays an important role in the detection of both structural and functional abnormalities in this group of patients. Fetal echocardiography can help in the early recognition of DS by detecting soft markers of DS, but its main role is to define the exact nature of the suspected cardiac problem in the fetus. Postnatal echocardiography is mandatory in the first month of life for all neonates with DS. It is also indicated before any cardiac surgery and for serial follow-up after cardiac surgery. In this article, we discuss the types and mechanism of cardiac abnormalities in DS children and the role of both fetal and postnatal echocardiography in the detection of these abnormalities.
Can maternal risk factors influence the presence of major birth defects in infants with Down syndrome?
Antenatal diagnosis of congenital heart disease and Down's syndrome: the potential effect on the practice of paediatric cardiology
A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart
A preliminary study of sonographic grading of fetal intracardiac echogenic foci: feasibility, reliability and association with aneuploidy
Dscr1, a novel endogenous inhibitor of calcineurin signaling, is expressed in the primitive ventricle of the heart and during neurogenesis
Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy
Identification, genomic organization and mRNA expression of CRELD1, the founding member of a unique family of matricellular proteins
Correlation between abnormal cardiac physical examination and echocardiographic findings in neonates with Down syndrome
Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn
Sequential segmental analysis in complex fetal cardiac abnormalities: a logical approach to diagnosis
CRELD1 mutations contribute to the occurrence of cardiac atrioventricular septal defects in Down syndrome
Down syndrome associated with hypothyroidism and chronic pericardial effusion: echocardiographic follow-up
Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes
Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project
The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies
Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease
Prevalence of congenital heart defects and persistent pulmonary hypertension of the neonate with Down syndrome
Origin and development of the atrioventricular myocardial lineage: insight into the development of accessory pathways
Screening for Congenital Heart Disease in Infants with Down Syndrome: Is Universal Echocardiography Necessary?
Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts
Identifying Patients with Atrioventricular Septal Defect in Down Syndrome Populations by Using Self-Normalizing Neural Networks and Feature Selection
Susceptibility to Heart Defects in Down Syndrome Is Associated with Single Nucleotide Polymorphisms in HAS 21 Interferon Receptor Cluster and VEGFA Genes.
Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.
Biomarkers for Cardiovascular Risk Assessment
Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.